Compare Adaptive Biotechnologies Corp (ADPT) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ING Groep NV — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while ING Groep NV trades at $31.96 (market cap $92.35B). The key difference: ING Groep NV is far larger — about 27.7× Adaptive Biotechnologies Corp's market cap, and ING Groep NV pays a 3.93% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ING | |
|---|---|---|
Market Cap | $3.33B | $92.35B |
Sector | Health | Financials |
52-Week High | $22.37 | $32.96 |
52-Week Low | $10.24 | $22.45 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ING trades at $32.24, up 0.44% today, with a bullish technical outlook supported by moving averages. The stock shows consistent earnings beats and a 27.84% net income margin. Recent news highlights strategic moves like a global subscription banking model and board appointments, reinforcing growth initiatives. Analyst consensus is strongly positive with 62.5% buy ratings.
The outlook remains favorable due to solid fundamentals and bullish sentiment, though risks include volatile cash flows and macroeconomic pressures. Upside potential is supported by a DCF intrinsic value of $34, suggesting modest appreciation from current levels. Investors should weigh strong profitability against sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
